Home Featured Page 247

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

PTSF75 – Possession Limits, Religion, and Scalability

Glow Time: PsychLight Brings a Powerful Tool to Psychedelic Research

Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate...

Red Light Closes Acquisition of Mera Life Sciences and Files Quarterly...

Distinguished Psychedelic Researcher, Professor of Psychiatry and Neuroscience, Rachel Yehuda, PhD,...

Red Light Holland Successfully Completes Canada’s Largest Legal Sale and Import...

MINDCURE Announces Financial Results for Fiscal 2021

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling...

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a...

Filament Health Files 20th Patent Application Including Three International PCT Applications

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

PTSF75 – Possession Limits, Religion, and Scalability

Glow Time: PsychLight Brings a Powerful Tool to Psychedelic Research

Mindset Pharma Announces its Next Generation Novel 5-MeO-DMT Psychedelic Analogs Demonstrate...

Red Light Closes Acquisition of Mera Life Sciences and Files Quarterly...

Distinguished Psychedelic Researcher, Professor of Psychiatry and Neuroscience, Rachel Yehuda, PhD,...

Red Light Holland Successfully Completes Canada’s Largest Legal Sale and Import...

MINDCURE Announces Financial Results for Fiscal 2021

Field Trip Health Ltd. Announces Launch Of “Kap Co-Operative” Program, Enabling...

MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a...

Filament Health Files 20th Patent Application Including Three International PCT Applications

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY